» Articles » PMID: 27789475

Synergy Between Tissue Factor and Exogenous Factor XIa in Initiating Coagulation

Overview
Date 2016 Oct 30
PMID 27789475
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Recent evidence suggests involvement of coagulation factor XIa (FXIa) in thrombotic event development. This study was conducted to explore possible synergies between tissue factor (TF) and exogenous FXIa (E-FXIa) in thrombin generation.

Approach And Results: In thrombin generation assays, for increasing concentrations of E-FXIa with low, but not with high TF concentrations, peak thrombin significantly increased whereas lag time and time to peak significantly decreased. Similar dependencies of lag times and rates of thrombin generation were found in mathematical model simulations. In both in vitro and in silico experiments that included E-FXIa, thrombin bursts were seen for TF levels much lower than those required without E-FXIa. For in silico thrombin bursts initiated by the synergistic action of TF and E-FXIa, the mechanisms leading to the burst differed substantially from those for bursts initiated by high TF alone. For the synergistic case, sustained activation of platelet-bound FIX by E-FXIa, along with the feedback-enhanced activation of platelet-bound FVIIIa and FXa, was needed to elicit a thrombin burst. Furthermore, the initiation of thrombin bursts by high TF levels relied on different platelet FIX/FIXa binding sites than those involved in bursts initiated by low TF levels with E-FXIa.

Conclusions: Low concentrations of TF and exogenous FXIa, each too low to elicit a burst in thrombin production alone, act synergistically when in combination to cause substantial thrombin production. The observation about FIX/FIXa binding sites may have therapeutic implications.

Citing Articles

A new look at TFPI inhibition of factor X activation.

Santiago F, Kaur A, Bride S, Monroe D, Leiderman K, Sindi S PLoS Comput Biol. 2024; 20(11):e1012509.

PMID: 39546494 PMC: 11567595. DOI: 10.1371/journal.pcbi.1012509.


Mathematical modeling identifies clotting factor combinations that modify thrombin generation in normal and factor VIII-, IX-, or XI-deficient blood.

Stobb M, Neeves K, Monroe D, Sindi S, Leiderman K, Fogelson A Res Pract Thromb Haemost. 2024; 8(7):102570.

PMID: 39434958 PMC: 11491717. DOI: 10.1016/j.rpth.2024.102570.


Inhibition of platelet-surface-bound proteins during coagulation under flow I: TFPI.

Miyazawa K, Fogelson A, Leiderman K Biophys J. 2022; 122(1):99-113.

PMID: 36403087 PMC: 9822800. DOI: 10.1016/j.bpj.2022.11.023.


DEVELOPMENT OF FIBRIN BRANCH STRUCTURE BEFORE AND AFTER GELATION.

Fogelson A, Nelson A, Zapata-Allegro C, Keener J SIAM J Appl Math. 2022; 82(1):267-293.

PMID: 36093310 PMC: 9455619. DOI: 10.1137/21m1401024.


A MATHEMATICAL MODEL OF PLATELET AGGREGATION IN AN EXTRAVASCULAR INJURY UNDER FLOW.

Link K, Sorrells M, Danes N, Neeves K, Leiderman K, Fogelson A Multiscale Model Simul. 2021; 18(4):1489-1524.

PMID: 33867873 PMC: 8051825. DOI: 10.1137/20m1317785.


References
1.
Burnouf T . A therapeutic, highly purified factor XI concentrate from human plasma. Transfusion. 1992; 32(9):861-7. DOI: 10.1046/j.1537-2995.1992.32993110761.x. View

2.
Koedam J, Hamer R, Bouma B, Sixma J . The effect of von Willebrand factor on activation of factor VIII by factor Xa. Eur J Biochem. 1990; 189(2):229-34. DOI: 10.1111/j.1432-1033.1990.tb15481.x. View

3.
Woodruff R, Grigg A, Firkin F, Smith I . Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet. 1986; 2(8500):217-8. DOI: 10.1016/s0140-6736(86)92511-0. View

4.
Griffiths A, Wintermute J, Newell-Caito J, Fay P . Residues flanking scissile bonds in Factor VIII modulate rates of cleavage and proteolytic activation catalyzed by Factor Xa. Biochemistry. 2013; 52(45):8060-8. DOI: 10.1021/bi4010123. View

5.
Neuenschwander P, Jesty J . A comparison of phospholipid and platelets in the activation of human factor VIII by thrombin and factor Xa, and in the activation of factor X. Blood. 1988; 72(5):1761-70. View